Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis

To assess the humoral response to vaccination against SARS-CoV-2 in patients with rheumatoid arthritis treated with methotrexate (MTX). In total, 142 fully vaccinated individuals were included at 6 ± 1 weeks after their second vaccination [BioNTech/Pfizer (70.4%), AstraZeneca (20.4%), and Moderna (9...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuchtenberger, Martin, Kovacs, Magdolna Szilvia, Eder, Anna, Nigg, Axel, Schäfer, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012944/
https://www.ncbi.nlm.nih.gov/pubmed/35429290
http://dx.doi.org/10.1007/s00296-022-05123-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012944/
https://www.ncbi.nlm.nih.gov/pubmed/35429290
http://dx.doi.org/10.1007/s00296-022-05123-2

Ejemplares similares